

The First Step to Diagnosing WHIM Syndrome Is Suspecting It

WHIM syndrome is a rare, combined primary immunodeficiency and a chronic neutropenic disorder, named for the manifestations of:

Warts | **H**ypogammaglobulinemia | **I**nfections | **M**yelokathexis

Less than 1 in 4 patients with WHIM syndrome present with all 4 manifestations.

The onset, severity, duration, and frequency of WHIM syndrome symptoms and potential resulting complications can be variable.²

Prevalence of Manifestations, Laboratory Findings, and Associated Complications^{2,3}

Classic WHIM Manifestations*

Warts **40%**

Hypogammaglobulinemia **65%**

Infections **92%**

Myelokathexis[†] **~100%**

WHIM syndrome is heterogeneous, and only **23%** of patients will typically present with the full tetrad of key manifestations.²

Frequent Laboratory Findings*

Neutropenia **98%**

Lymphopenia **88%**

Monocytopenia

Exact prevalence unknown

WHIM syndrome should be suspected in any case of chronic neutropenia with lymphopenia and/or monocytopenia.⁴

Multisystemic Complications*

Sepsis

13%

Resulting from bacterial meningitis and bacteremia

End-organ damage

20%

Bronchiectasis and hearing loss


Pneumonia

63%

Cancer

30%

Estimated overall risk by age 40, including HPV- and EBV-associated malignancies[‡]



*Based on analysis of n=66 patients, as described in Geier et al.

[†]Includes leukopenia in cases where bone marrow biopsy was not performed.

[‡]Based on analysis of n=60 patients, as described in Beaussant Cohen et al.



SCAN ME


Suspect your patient might have WHIM?
Connect with an X4 Diagnostic Liaison
to learn more.

WhatIfItsWHIM.com

X4
PHARMACEUTICALS

Early Diagnosis of WHIM Syndrome is Essential


Incidence of End-Organ Damage Based on Diagnostic Delay²



- In a retrospective analysis, earlier diagnosis and treatment resulted in fewer hospitalizations and lower incidence of end-organ damage, including bronchiectasis and hearing loss.²
- An early, definitive WHIM diagnosis can help inform and guide patient management, improve outcomes, and may help reduce potential antibiotic resistance and long-term complications.^{2,5}

WHIM Syndrome 3-Point Diagnosis

Clinical evaluation, bone marrow biopsy and/or genetic testing can help inform a WHIM syndrome diagnosis²



Phenotype and Patient/Family History^{2,6}

Frequent Infections

- Recurrent sinopulmonary and upper respiratory tract infections
- History of frequent childhood ear infections
- Subcutaneous abscesses
- Absence of classic opportunistic infections

Recalcitrant Warts

- Consistent presence of HPV warts
- Anogenital warts
- Resistance to therapy

Laboratory Findings^{2,4}

Neutropenia

- ANC ≤ 1000 cells/ μ L (elevated during infection but low with recovery)

Lymphopenia

- ALC < 1500 cells/ μ L (age appropriate)

Monocytopenia

Hypogammaglobulinemia

- Low circulating levels of IgG, IgA, and/or IgM



SCAN ME **Path4Ward**

Order no-cost genetic testing to diagnose or rule out WHIM syndrome through **Path4Ward**

References: 1. Dale DC, Firkin F, Bolyard AA, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. *Blood*. 2020;136(26):2994-3003. 2. Geier CB, Ellison M, Cruz R, et al. Disease progression of WHIM syndrome in an international cohort of 66 pediatric and adult patients. *J Clin Immunol*. 2022;42(8):1748-1765. 3. Beausant Cohen S, Fenneteau O, Plouvier E, et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. *Orphanet J Rare Dis*. 2012;7:71. 4. Badolato R, Donadieu J; WHIM Research Group. How I treat warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. *Blood*. 2017;130(23):2491-2498. 5. Kawai T, Malech HL. WHIM syndrome: congenital immune deficiency disease. *Curr Opin Hematol*. 2009;16(1):20-26. 6. Heusinkveld LE, Majumdar S, Gao JL, McDermott DH, Murphy PM. WHIM syndrome: from pathogenesis towards personalized medicine and cure. *J Clin Immunol*. 2019;39(6):532-556. Path4Ward is a testing program sponsored by X4. All tests and services are performed by Invitae. © 2023 X4 Pharmaceuticals, Inc. All rights reserved. X4NM-US-000-2300022 (v1.0)

